FDA Oversight of Compounding Pharmacies
Compounding pharmacies occupy a distinct regulatory space within U.S. drug law, operating under statutory frameworks that differ materially from the approval pathways governing commercially manufactured drugs. FDA oversight of compounding is shaped by the Drug Quality and Security Act (DQSA) of 2013 and the older Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), creating a tiered system that determines which federal and state requirements apply to a given pharmacy. Understanding this framework is essential for pharmacists, prescribers, healthcare facilities, and patients who rely on compounded preparations that fall outside standard commercial supply chains. For broader context on FDA's regulatory reach, the FDA Authority overview provides foundational grounding.
Definition and Scope
Compounding is the process by which a licensed pharmacist or physician combines, mixes, or alters pharmaceutical ingredients to create a drug tailored to the needs of an individual patient — for example, a formulation free of a specific allergen, a pediatric dose unavailable commercially, or a route of administration not offered by an approved product.
FDA authority over compounding derives from two primary statutory provisions:
- Section 503A of the FD&C Act (21 U.S.C. § 353a) — governs traditional pharmacies compounding for identified individual patients based on a valid prescription.
- Section 503B of the FD&C Act (21 U.S.C. § 353b) — governs outsourcing facilities, a category created by the DQSA in 2013 to regulate higher-volume compounding operations that supply healthcare facilities.
The scope of FDA oversight is not uniform: traditional pharmacies operating under 503A are primarily regulated by state boards of pharmacy, while 503B outsourcing facilities are subject to direct federal oversight including registration requirements, current Good Manufacturing Practice (cGMP) standards, and routine FDA inspection.
How It Works
The operational structure of FDA compounding oversight functions along two parallel tracks, distinguished by the compounder's registration status and volume of production.
Track 1 — Section 503A (Traditional Pharmacy Compounding)
A pharmacy qualifies for 503A exemptions from FDA approval, labeling, and cGMP requirements if it:
- Compounds based on a valid prescription for an identified individual patient.
- Does not compound commercially available drug products that are essentially copies of approved drugs (with limited exceptions).
- Does not compound drugs that appear on FDA's list of drugs withdrawn from the market for safety or efficacy reasons.
- Uses bulk drug substances that either appear on FDA's 503A bulks list (published by FDA's Center for Drug Evaluation and Research) or are components of an FDA-approved drug.
State boards of pharmacy retain primary enforcement authority over 503A pharmacies, though FDA retains jurisdiction when interstate commerce is involved or when products pose safety risks.
Track 2 — Section 503B (Outsourcing Facilities)
Outsourcing facilities voluntarily register with FDA and, in exchange, may compound without patient-specific prescriptions and distribute to healthcare facilities across state lines. The regulatory obligations are substantially heavier:
- Compliance with cGMP standards (21 C.F.R. Parts 210 and 211) equivalent to those applied to conventional drug manufacturers.
- Biannual reporting of drug products compounded and distributed.
- Routine FDA inspections — the same inspection process described in detail on the FDA inspection process page.
- Adverse event reporting obligations under FDA's MedWatch and safety reporting systems.
As of 2023, FDA listed approximately 80 registered outsourcing facilities on its public registry (FDA Outsourcing Facility List).
Common Scenarios
Compounding oversight issues arise in predictable operational contexts:
Drug Shortages — When an FDA-approved drug enters shortage, demand for compounded alternatives surges. FDA maintains a shortage list that can temporarily authorize compounding of products that would otherwise be prohibited as essentially copies of approved drugs. The mechanics of shortage-driven policy are covered in detail on the FDA drug shortage management page.
Essentially Copies — A compounder preparing a drug that is essentially a copy of a commercially available approved product without a demonstrable clinical difference for the patient violates 503A. FDA has issued guidance defining "essentially a copy" and has taken enforcement action against pharmacies that systematically prepare stock batches without individual prescriptions.
Hospital and Clinic Supply — Healthcare facilities frequently source compounded sterile preparations (CSPs) — IV admixtures, epidural solutions, ophthalmic preparations — from outsourcing facilities. Following the 2012 fungal meningitis outbreak linked to the New England Compounding Center, which caused 64 deaths (CDC investigation records), Congress enacted the DQSA specifically to close the regulatory gap that allowed large-scale compounding without federal oversight.
Veterinary Compounding — Compounding for animal patients follows a separate but parallel framework, addressed through FDA's Center for Veterinary Medicine (FDA veterinary medicine oversight).
Decision Boundaries
The critical regulatory distinctions that determine which framework applies to a compounding operation are:
| Factor | Section 503A | Section 503B |
|---|---|---|
| Patient-specific prescription required | Yes | No |
| Registration with FDA required | No | Yes (voluntary) |
| cGMP compliance required | No | Yes |
| May distribute across state lines | Limited | Yes |
| FDA inspection authority | Limited | Direct and routine |
| Labeling exemptions | Yes | Partial |
The "essentially a copy" boundary is among the most litigated and guidance-intensive areas. A compounder may argue clinical difference — a different concentration, a different excipient profile for an allergic patient — to escape the prohibition. FDA evaluates these claims on a product-by-product basis.
The bulk drug substance question is similarly contested. A substance not yet on FDA's 503A or 503B bulks lists may still be used if it meets interim criteria, but FDA has issued enforcement discretion policies with defined timelines for substances under active review. Pharmacies operating outside those timelines risk warning letters, injunctions, and product seizure under FDA enforcement actions.
Interstate distribution triggers federal authority over 503A pharmacies that would otherwise fall primarily under state oversight. A pharmacy that ships compounded products to patients or providers in other states moves into a zone where FDA has consistently asserted jurisdiction regardless of whether the pharmacy has registered as a 503B outsourcing facility.